Jerry is an expert who is passionate about culture, leadership development, learning, inclusion and diversity, and talent management – he frequently publishes articles and speaks on these topics at conferences. He’s also authored a course on culture change for Linkedin Learning that has been translated into 10 languages and viewed over 300k times, his second course on talent management was released in March 2022, and has already been viewed over 6k times.

Jerry has 20 + years of international consulting and in-house experience leading regional and global teams in the US, Europe and Asia with leading companies in the technology, FMCG, pharmaceutical, professional and financial services sectors: Daiichi Sankyo, Allianz, Google, Ernst & Young, Wells Fargo, ABB, Daniel Swarovski and W.L. Gore. He is skilled at coaching, facilitating, developing and advising leaders at all levels including senior executives, and has strong intercultural skills, that were developed by working with diverse clients and students from many countries.

In his current role, he is leading the company’s Global Culture Transformation Initiative and is reporting to Daiichi Sankyo’s CHRO in Tokyo. In 2020 he led a global project team to perform an in-depth cultural diagnostic in collaboration with McKinsey to identify the desired culture the company needed to develop in order to achieve its business goal of becoming a leading global pharma innovator. He is currently leading the initiative in collaboration with Korn Ferry to ensure the successful adoption and embedding of the company’s new Core Behaviors developed from the diagnostic.

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its more than 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.